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Partial androgen insensitivity syndrome (PAIS) is associated with impaired male genital development and can be transmitted
through mutations in the androgen receptor (AR). The aim of this study is to develop a cell model suitable for studying the
impact AR mutations might have on AR interacting proteins. For this purpose, male genital development relevant mouse cell lines
were genetically modified to express a tagged version of wild-type AR, allowing copurification of multiprotein complexes under
native conditions followed by mass spectrometry. We report 57 known wild-type AR-interacting proteins identified in cells grown
under proliferating and 65 under nonproliferating conditions. Of those, 47 were common to both samples suggesting diﬀerent AR
protein complex components in proliferating and proliferation-inhibited cells from the mouse proximal caput epididymus. These
preliminary results now allow future studies to focus on replacing wild-type AR with mutant AR to uncover diﬀerences in protein
interactions caused by AR mutations involved in PAIS.
1. Background
Androgen insensitivity gives rise to a wide spectrum of disor-
ders in man, the most severe being complete sex reversal, to
milder forms of PAIS associated with ambiguous or under-
developed genitalia, or even milder forms causing “only”
male infertility in otherwise healthy males. Often mutations
in the androgen receptor (AR) are involved which interfere
with ligand binding, DNA binding, or increase or decrease
intramolecular interactions between AR domains [1]. Where
no mutations are identified in the AR [2] mutations in
AR coregulators may be implicated in failure to activate or
repress androgen-regulated target genes. Although there are
a number of mouse models available to study impaired AR
function in vivo [3], the signalling networks are too complex
to dissect without using simpler cell models. The aim of
this study was to develop a cell model for the study of AR
signalling in the urogenital tract. In turn this may identify
disrupted signalling resulting from AR mutations associated
with PAIS. Male genital development relevant murine cell
lines PC1 (proximal caput epithelial cells from mouse
epididymus) [4] andMFVD (mesenchymal fetal vas deferens
cells) [5] were genetically modified to express a tagged
wild-type AR to test the system. The modifications allow
purification of multiprotein complexes associated with AR
under native conditions and analysis of the copurified pro-
tein complexes by mass spectrometry. The data was analysed
using readily available bioinformatics software: the pathway
mining tool of “DAVID” bioinformatics resources [6, 7] and
the gene group functional profiling tool of g : profiler [8]. By
focussing solely on known AR coregulators, we were able (as
a proof of principle) to uncover diﬀerences in the proteome
of proliferating and nonproliferating epithelial PC1 cells.
2. Methods
2.1. N-Terminal Tandem Aﬃnity Purification Tag (N-TAP).
The N-TAP was designed by modifying the C-terminal
tandem aﬃnity tag (C-TAP) from Ferna´ndez et al., 2009 [9].
The HAT tag was amplified, using the C-terminal tag [9] as
a template and PCR primers (Figure 1(a)) designed to add
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Figure 1: Creation of themouseN-TAP-mAR. (a) Amplification of the TEV-HAT-glycine alanine repeat sequence with primers F and R using
the C-TAP from Ferna´ndez et al., 2009 [9] as template. (b) Aminoacid sequence of the complete NH2-terminus of the androgen receptor.
The N-TAP increases the size of the mAR by 70 amino acids and the molecular weight by 7.8 kDa (http://web.expasy.org/compute pi/). (c)
Schematic showing the tagged androgen receptor (N-TAP-mAR) cDNA clone. The N-terminal TAP tag was selected on the basis of small
size. It contains three FLAG epitopes (3xFLAG) and 6xHistidine residues (HAT) located in an alpha helix.
the TEV protease cleavage site with the forward primer and
the glycine-alanine repeat and an additional NotI-cloning
site with the reverse primer. The HindIII-NotI fragment
was then inserted into the polylinker region of p3XFLAG-
CMV-10 (Sigma) in frame with 3XFLAG (Figure 1(b)). The
mouse androgen receptor cDNA clone (gift from Professor
Jan Trapman, Department of Pathology, Erasmus MC/JNI
Rotterdam) was modified by replacing the start methionine
ATG with an NotI site-by-site directed mutagenesis (Strata-
gene) and introducing the 2.787 kb NotI-BHI full length
mouse cDNA into the N-TAP-CMV-10 vector (Figure 1(c)).
The N-TAP-mAR fusion construct was confirmed by
sequencing.
2.2. Transient Transfection and Luciferase Assay. In total 105
COS-1 or Hela cells/well were seeded into 12-well tis-
sue culture plates in DMEM, containing 10% charcoal-
stripped serum. Cells were transiently transfected using
Fugene (Roche) or Lipofectamine 2000 (Invitrogen) with
25 ng AR or N-TAP-mAR, 500 ng of pGRE-luciferase
and 25 ng pTK-RL according to manufacturer’s instruc-
tions. 12–16 hours after transfection, the medium was
replaced with DMEM, containing 10% charcoal-stripped
serum + or −10 nM dihydrotestosterone (DHT; Sigma).
24 h later, cells were harvested and lysed in 25mM
glycine (pH 7.8), 15mM MgSO4, 4mM EGTA, 1% tri-
ton × 100 and 1mM dithiothreitol. Luciferase assays
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were performed with reagents from nanolight technology
and the ratio of luciferin : renillaluciferase activity was
measured using a Turner TD-20/20 luminometer. Stan-
dard error bars relate to three independent transfection
experiments.
2.3. Control Cell Lines. Androgen responsive cell lines PC1
andMFVD from themouse urogenital tract served as control
cell lines in their nonmodified state. The PC 1 cell line was
a gift from Araki et al. [4] and the MFVD cell line a gift
from Umar et al. [5]. The PC1 cell line is an epididymal
cell line immortalized with SV 40 large T-antigen and has
been characterized in great detail regarding morphology
[4], epithelial and epididymus specific gene expression
[4], and androgen responsiveness [10]. Also the MFVD
cell line is immortalized by expression of a temperature
sensitive SV 40 large T-antigen but of mesenchymal origin.
MFVD cells were derived from fetal (18 d.p.f.) mouse vas
deferens and show features of Wolﬃan duct mesenchymal
cells and androgen responsiveness [5]. Both cell lines were
continuously cultured under conditions given elsewhere
[4, 5] in the presence of 5 nM mibolerone, a synthetic
androgen.
2.4. Establishment of Stable Cell Lines. The control cell lines
PC1 and MFVD were transfected with the ScaI (unique
site in the bacterial ampicillin resistance) linearised N-TAP-
mAR vector using Lipofectamine 2000 (Invitrogen). After
48 hours, transfected cells were replated in dilutions from
105–103 cells/14 cm diameter dish and G418 resistant clones
were selected with 750 μg/mL G418 (PC1) and 250 ug/mL
G418 (MFVD). Single colonies coming up were picked with
cloning rings, grown up and tested for N-TAP-mAR expres-
sion by Western blot analysis and immunocytochemistry
using the FLAG M2 antibody (Sigma) and the AR-N20
antibody (Santa Cruz).
2.5. Growth of Proliferating and Nonproliferating PC1 and
P17 Cells. PC1 cells, derived from the mouse proximal
caput epididymus and immortalized by expression of a
temperature sensitive SV 40 large T-antigen, were continu-
ously cultured at 33◦C, the permissive temperature of large
T in the presence of 5 nM mibolerone. At physiological
temperature (37◦C), cell growth is partly inhibited and
T-antigen-expressing cells can survive [11]. Large T is
however degraded after prolonged exposure of the cells
to the nonpermissive temperature (39◦C), then significant
cell death occurs and the cells do not recover [11]. To
prevent cell death but still have an inhibitory eﬀect on
proliferation early passage PC1 and P17 cells were cultured
to near confluence at 33◦C and kept then for 1 week at
37◦C in growth medium containing 5 nM mibolerone before
preparing cytoplasmic and nuclear extracts of the still healthy
looking cells. For extracts made from proliferating PC1 and
P17 cells, the cells were grown at 33◦C in growth medium
containing 5 nM mibolerone. Similar amounts of cell pellets
from proliferating and nonproliferating cells were processed
for protein extraction.
2.6. Immunoblotting. Cells from subconfluent cultures were
washed, trypsinized, and pelleted by centrifugation and
washed 3x in cold PBS. For whole cell lysates, cells were
lysed in SDS loading buﬀer (0.03125M Tris pH 6.8, 5%
glycerol, 0.001% bromphenol blue 3, 1% SDS, 2.5% β-
mercaptoethanol). Samples were subjected to sodium
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE), transferred to polyvinylidene difluoride membrane,
blocked and probed in phosphate-buﬀered saline (150mM
NaCl, 3mMKCl, 10mM phosphate salts (mono and dibasic)
(pH 7.3), 0.05% (vol/vol) Tween 20) containing 10% nonfat
dry milk. Primary antibodies were used at recommended
dilutions and horseradish peroxidase-conjugated secondary
antibodies (Dako) and ECL Plus Blotting Detection Reagents
(Amersham) or SuperSignalWest Femto (Thermo Scientific)
were used as described in the manufacturer’s instructions.
SRC-1 (128E7) and CTNNB1 (9587) antibodies were pur-
chased from NEB, FLAG M2 (F3165) from Sigma, and
N20-AR (Sc-816), NR3C1 (Sc-8992), SMARCC1 (Sc-9748),
ACTB (Sc-81178) from Santa Cruz.
2.7. Cytoplasmic and Nuclear Protein Extraction and Purifi-
cation of N-TAP-mAR. The protein extraction protocol is a
modified version of a chromatin extraction protocol for co-
purification of histones by Saade et al., 2009 [12]. Cells were
grown on 14 cm diameter dishes to confluence (10 plates PC1
or 20 plates P17 gave about 700 μL cell volume), washed 3x
with prewarmed PBS, trypsinised with 1mL trypsin-EDTA
(Sigma)/plate 5 minutes 37◦C, inactivated with medium,
pooled in 50mL Falcon, spun1200 rpm 5mins RT, and
washed 3x with cold (4◦C) PBS. Cells were transferred to
a 2mL microfuge tube and pelleted by centrifugation at
6500 rpm 2-3 minutes at 4◦C. Pellets (2 × 200 μL) were
resuspended in 2 × 1.8mL hypotonic buﬀer (10mM Tris
pH 7.5, 10mM KCl, 1.5mM MgCl, 0.1% Triton, 4.5mM β-
mercaptoethanol, protease inhibitor cocktail (Roche), 5 nM
mibolerone, 1mM Pefabloc (Roche), and Phosstop (Roche))
by pipetting up and down and vortexing vigorously on high-
est setting for 15 seconds followed by 45 minute incubation
on ice vortexing every 10 minutes. Nuclei were spun down at
4◦C 13.000 RPM for 5 minutes, the supernatant, called here
cytosol fraction, transferred to a clean tube and NaCl was
added to 15mM. This cytosol fraction was added to FLAG-
M2 coupled magnetic beads (ca. 5mg) after keeping an
aliquot as cytosol input fraction for PAGE. Coupling of the
magnetic beads (Dynabeads M-270 Epoxy from Invitrogen)
to the FLAG M2 antibody (Sigma F3165) was performed
according to manufacturer’s instructions. Cytosol extracts
on beads rotated for 1 hour minimum at 4◦C. Nuclei were
taken up in sucrose buﬀer (0.34M sucrose, 10mM Tris
pH8, 3mM MgCl2, 1mM CaCl2, 150mM NaCl, 1mM
DTT, protease inhibitor cocktail (Roche), 5 nM mibolerone,
1mM Pefabloc (Roche), Phosstop (Roche)) 150 μL/100 μL
cell pellet and resuspended. 0.3 units micrococcal nuclease
from Sigma (0.1U/μL in 10mM Tris/0.1mM CaCl2 pH8)
for 100 μL nuclear extract were added and incubated for
30min at 37◦C. Extracts were then diluted with 1 volume
of sucrose buﬀer and sonicated 6 × 10 seconds on ice with
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10 sec bursts and 10 sec cool downs alternating. Extracts were
finally loaded onto FLAG M2-coupled magnetic beads and
rotated for at least 1 hour at 4◦C in cold room. Supernatants
were kept as flow through and aliquots before loading on
to the beads as nuclear input. After the incubation period,
beads loaded with cytosol preparations were washed 3x with
hypotonic wash buﬀer (10mM Tris pH 7.5, 10mM KCl,
1.5mM MgCl, 0.1% Triton, 4.5mM β-mercaptoethanol,
protease inhibitor cocktail (Roche), 5 nM mibolerone, 1mM
Pefabloc (Roche) and Phosstop (Roche), 0.5% NP40, 0.05%
sodium deoxycholate, 0.005% SDS, 15mM NaCl) or sucrose
buﬀer (nuclear preps) followed by 3 washes with TEV
buﬀer (0.05M Tris pH 8, 1mM DTT, 0.5mM EDTA)
supplemented with Protease Inhibitor Cocktail (Roche),
mibolerone (5 nM), and phosphatase inhibitors (Phosstop
and Pefabloc (Roche), and NaCl to15mM NaCl in cytosolic
and 150mM NaCl in nuclear TEV buﬀer. The beads were
finally taken up in 100 uL TEV buﬀer and bound protein
complexes were eluted with 10 units of TEV protease
(GST-tag) (TEVP US Biological) at RT for 1 hour. Protein
concentration in the eluted fraction was determined by
Bradford assay. The beads were kept in PBS for recycling.
2.8. Mass Spectrometry. Colloidal coomassie stained protein
bands (Colloidal Blue Staining Kit, Invitrogen) were excised
out of a 5% PAGE after separation in 7 slices covering a size
spectrum of 48 kDa to the top of the gel. Gel slices were
briefly washed in MilliQ water and kept in water at −80◦C
until submitted to “Cambridge Proteomics Services” where
all LC-MS/MS experiments were performed using an Eksi-
gent NanoLC-1D Plus (Eksigent Technologies, Dublin, CA)
HPLC system and an LTQ Orbitrap Velos mass spectrometer
(ThermoFisher, Waltham, MA). Separation of peptides was
performed by reverse-phase chromatography used at a flow
rate of 300 nL/min and an LC-Packings (Dionex, Sunnyvale,
CA) PepMap 100 column (C18, 75 μM i.d. × 150mm,
3 μM particle size). Peptides were loaded onto a precolumn
(Dionex Acclaim PepMap 100 C18, 5 μM particle size, 100A,
300 μM i.d.× 5mm) from the autosampler with 0.1% formic
acid for 5 minutes at a flow rate of 10 μL/min. After this
period, the valve was switched to allow elution of peptides
from the precolumn onto the analytical column. Solvent A
was water + 0.1% formic acid and solvent B was acetonitrile
+ 0.1% formic acid. The gradient employed was 5–50% B
in 45 minutes. The LC eluant was sprayed into the mass
spectrometer by means of a new objective nanospray source.
All m/z values of eluting ions were measured in an Orbitrap
Velos mass analyzer, set at a resolution of 30000. Data
dependent scans (Top 20) were employed to automatically
isolate and generate fragment ions by collision-induced
dissociation in the linear ion trap, resulting in the generation
of MS/MS spectra. Ions with charge states of 2+ and above
were selected for fragmentation.
2.9. Data Processing and Database Searching. After run, the
data were processed using Protein Discoverer (version 1.2.,
ThermoFisher). Briefly, all MS/MS data were converted to
mgf (text) files. These files were then submitted to theMascot
search algorithm (Matrix Science, London UK) and searched
against Uniprot Mouse database, using a fixed modification
of carbamidomethyl and variable modifications of oxidation
(M).
3. Results
3.1. Isolation of N-TAP-mAR Complex in MFVD and PC1
Cell Lines. Stable MFVD and PC1 clones expressing N-
TAP-mAR were developed as described in Section 2. Total
protein was extracted from several clones and analyzed for
N-TAP-mAR expression by Western blot using FLAG and
AR-specific antibodies (data not shown). A second criteria
was the nuclear localization of N-TAP-mAR, which was
examined in several clones by immunofluorescence using
FLAG and AR-specific antibodies. One MFVD cell line (M7)
and one PC1 cell line (P17) were selected on the basis
that they expressed similar levels of stably integrated N-
TAP-mAR and endogenous wild-type AR (WT AR). Both
were predominantly located in the nucleus when grown in
medium supplemented with 5 nM mibolerone (Figure 2(a)).
The transactivation properties of N-TAP-mAR were tested
in COS cells by cotransfection of a GRE reporter construct,
with expression levels confirmed by Western blot (Figures
2(b) and 2(c)). Levels of expression are stable, allowing
considerable grow up of cells.
Diﬀerent protein purification protocols for producing
nuclear and cytosol cell extracts were tested. Commer-
cially available purification kits and a modified version
of a chromatin purification protocol (FLAG-antibody cap-
ture) were compared and the latter was chosen. FLAG-
antibody capture gave a good recovery of N-TAP-mAR
when preparing extracts from M7 (Figure 3(a)) or P17 cells
(Figure 3(b)). The known coregulators SRC-1 and CTNNB1
were copurified in P17 extracts but not in M7 extracts.
Attempts to optimize His-tag purification conditions were
unsuccessful; Nickel aﬃnity purification of the PC1 (N-
TAP-mAR negative control) chromatin extracts gave high
background with unspecific protein binding to the Nickel
resin. The cell lines proliferate at 33◦C with growth driven
by temperature sensitive SV40 T-antigen; and proliferation
stops at 37◦C. Figure 3(c) illustrates a preparative gel of TEV
protease-eluted proteins purified from the nuclei of P17 cells
cultured at 33◦C and 37◦C. The gel slices were selected for
LC- MS/MS, and data processed using the Mascot Search
engine at the Cambridge Centre for Proteomics.
The results from the LC-MS/MS search are portrayed as
peptide matches and grouped as protein hits using a sim-
ple parsimony algorithm (http://www.matrixscience.com/).
Only those ions scores that exceed a significance thresh-
old of 0.05 (1 in a 20 chance of being a false posi-
tive) contributed to the score. This would translate into
1500 peptides falling within the mass tolerance window
to have a score of ≥45. Known AR-interacting proteins
(http://androgendb.mcgill.ca) were identified among the
protein hits and are listed in Table 1 along with their respec-
tive peptide scores. In this first mass spec analysis, we
identified 1196 AR associated proteins in FLAG purified
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Figure 2: Nuclear localization and transactivation ability of N-TAP-mAR. (a) Immunostaining of a stable mesenchymal cell line M7 and a
stable epithelial cell line P17 expressing N-TAP-mAR. The FLAG antibody detects tagged androgen receptor only. N20 antibody recognises
both endogenous AR and N-TAP-mAR. Nuclei staining with DAPI indicates the percentage of cells expressing NTAP-mAR. (b) The ability
of the modified N-TAP-mAR and WT-AR to activate a glucocorticoid response element (GRE) was assayed in COS-1 cells in a transient
transfection luciferase assay. GRE promoter activation, shown here on the y-axis as luciferase/renilla ratio, was similar for the tagged and
nontagged androgen receptor. (c) Tagged androgen receptor expression (N-TAP-mAR) was elevated in the Western blot done with protein
extracts from the transactivation samples relative to WT.
extract from proliferating cells and 1456 from nonprolif-
erating cells. Of those 882 were common between those
two groups, 314 were only picked up in FLAG purifications
from proliferating cells and 574 were only picked up in
FLAG purifications from nonproliferating cells. Functional
profiling was carried out using web tools “DAVID” [6, 7] and
“g : profiler” [8], providing functional enrichments in the
form of pathways, biological processes, molecular functions,
metabolic functions, cellular localization, protein-protein
interactions, and shared transcription factor binding sites.
Only pathways and biological processes which received the
highest scores are utilized.
3.2. Analysis of Gene Lists with DAVID
Bioinformatics Resources [6, 7].
37◦C. The gene list of known AR-interacting proteins iden-
tified in the nuclear FLAG purifications of the 37◦C samples
(37 only + common, Table 1) was accepted as 65 DAVID ID’s
using DAVID bioinformatics resources [6, 7]. Gene ontology
tool “GOTERM BP FAT” gives the highest score to the
biological process (BP) “regulation of transcription” with 40
contributing genes (Table 2). Another high scoring biological
process “chordate embryonic development” listed 11 genes:
NCOR2, SMARCA4, AR, PSMC3, PRKDC, KDM1A, TRP53,
and EP300 common to both temperatures and MED1,
NF1, and SP1 specific to the 37◦C samples (Table 4). When
analyzing the gene list for pathways, 10 genes are components
of the Kegg Pathway: pathways in cancer: EP300, AR,
CTNNB1, DAPK3, HSP90, PIAS1, RB1, STAT3, HDAC1, and
TRP53. Of these 10 genes only STAT3, RB1, and DAPK3
have inhibitory function in this pathway. 6 of those 10 genes
(EP300, AR, CTNNB1, Hsp90, RB1, and TRP53) have been
associated with prostate cancer (Table 3).
The BIOCARTA Chart revealed overrepresented path-
ways: “telomeres, telomerase, cellular aging, and immor-
tality”, with 5 genes (XRCC5, XRCC6, HSP90, RB1, and
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Figure 3: FLAG purifications. (a) Western blot analysis of FLAG-purified M7 nuclear and cytosol extracts using TAP negative MFVD cells
as control. Compared are SRC1, beta catenin (CTNNB1), and AR expression in extracts before (NE/CE) and after (FLOW) purification and
in the TEV-eluted fractions. AR (WT and N-TAP-mAR comigrate) is recovered in TEV eluate from the M7 but not from the MFVD control
purifications. (b)Western blot analysis of FLAG-purified P17 nuclear and cytosol extracts using TAP negative PC1 cells as control. Compared
are SRC1, beta catenin, and AR expression in extracts before (NE/CE) and after (FLOW) purification and in the TEV-eluted fractions. AR
(WT and N-TAP-mAR are here distinguishable) is recovered in TEV eluate from the P17 but not from the PC1 control purifications. (c)
Coomassie stained 5% PAGE loaded with TEV-eluted fractions from the control cell line PC1 and the NTAP-mAR expressing cell line P17
grown at 33◦C and 37◦C after FLAG purification. This gel was prepared for cutting out gel slices (1–7), which were then submitted for mass
spectrometry. The arrows indicate the N-TAP-mAR migration. M is the size estimate by a prestained protein ladder in kilo Daltons (kDa).
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Table 1: List of only the known androgen-receptor-interacting proteins and coregulators (http://androgendb.mcgill.ca) identified after mass
spec analysis of all gel fractions (Figure 3(a)) from FLAG purifications of nuclear extracts from P17 cells grown under proliferating and
nonproliferating conditions (see Section 2). (a) Listed are the interacting proteins that were unique for the proliferating cells (33 only),
interacting proteins that were unique for the nonproliferating cells (37 only), and (b) interacting proteins common to both (common). The
AR is highlighted. Given are the Uniprot accession numbers identified by the database Mascot search (Uniprot), the score achieved in the
peptide summary report (score), the gel slice number (), and information whether the protein had been identified as a coactivator (CoA),
corepressor (coR), or the eﬀect has not been reported (—). Activating function has been allocated to GSN [13, 14], without distinguishing
between the 2 isoforms [15].
(a)
33 only coA/coR Score: P17/PC1 (slice) Uniprot 37 only coA/coR Score: P17 (slice) Uniprot
KDM3A CoA 52 (3) Q6PCM1 KDM5B coA 93 (5) Q80Y84
WHSC1 CoA 252 (5) Q8BVE8 DAPK3 coA 67 (1) O54784
MED17 CoA 66 (2) Q8VCD5 PIAS1 coA/CoR 38 (2) O88907
MED24 CoA 156 (3) A6PW47 MED1 coA 44 (6) Q925J9
ARID1B CoA 38 (6) E9Q4N7 GATA3 coA 55 (1) P23772
SRC — 57 (1) Q2M4I4 SP1 coA 81 (3) O89090
SMARCC1 CoA 1112/60 (5) Q3UNN4 TGFBI1 coA 32 (1) Q62219
SMARCD1 CoA 39 (1) Q61466 TRIM24 coA 165 (4) Q64127
NPM1 CoA 438 (6) Q5SQB0 FKBP5 coA 29 (1) Q64378
GTF2F1 — 89 (2) Q3THK3 RANBP10 coA 53 (2) Q6VN19
CALCOCO1 coA 156 (3) Q8CGU1
PSPC1 coA 35 (2) Q8R326
GAK coA 397 (5) Q99KY4
NCOA2 coA 68 (5) Q61026
NR3C1 coR 97 (3) Q06VW2
AP-1 coA/CoR 56 (2) Q3TXG4
RB1 coA 55 (5) Q3URY9
NF1 CoA 46 (7) Q04690-1
(b)
Common coA/coR
Score 33◦C:
P17/PC1 (slice)
Uniprot
Score 37◦C:
P17 (slice)
STAT3 CoA 41 (3) P42227 90 (3)
DAXX CoR 66 (4) Q3UIV3 70 (4)
ARID1A CoA 107 (5) A2BH40 78 (5)
HDAC1 CoR 428/52 (2) O09106 251 (2)
BRD7 CoR 169 (3) O88665 50 (3)
HSP90 CoR 719/250 (3) P07901 1089 (3)
GSN isoform1 [15] CoA ? 542 (4) P13020-1 516 (4)
GSN isoform2 [15] CoA ? 1879/624 (3) P13020-2 1688 (3)
CALR CoR 148 (1) P14211 612 (1)
HSPA1B CoA 434 (2) P17879 582 (2)
AR CoA 115 (4) P19091 200 (4)
XRCC6 CoA 1208/85 (2) P23475 1380 (2)
MCM3 CoA 728 (3) P25206 1476 (3)
XRCC5 CoA 1727/49 (3) P27641 1717 (3)
PA2G4 CoR 89/257 (1) P50580 54 (1)
ACTN4 CoA/CoR 3147/3229 (3) P57780 3112 (3)
ACTB CoA 1386 (1) P60710 1106 (1)
DNAJA1 CoR 173 (1) P63037 371 (1)
PRKDC CoA 1134 (7) P97313 739 (7)
CTNNB1 CoA 242/44 (3) Q02248 242 (3)
SMARCA4 CoA 1841/73 (6) Q3TKT4 1449 (6)
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(b) Continued.
Common coA/coR
Score 33◦C:
P17/PC1 (slice)
Uniprot
Score 37◦C:
P17 (slice)
MYST2 CoR 437 (2) Q5SVQ0 36 (2)
KHDRBS1 CoR 137/100 (2) Q60749 274 (2)
DDX5 CoA 1099/753 (2) Q61656 1150 (2)
SMARCA2 CoA 727 (6) Q6DIC0 789 (6)
PPP2R1A CoR 433 (1) Q76MZ3 97 (1)
RBM14 — 232/201 (2) Q8C2Q3 373 (2)
COBRA1 CoR 50 (6) Q8C4Y3 40 (6)
ATAD2 CoA 405 (5) Q8CDM1 2221 (5)
KIAA1967 CoA 39 (4) Q8VDP4 92 (4)
SFPQ CoA/CoR 766/446 (3) Q8VIJ6 490 (3)
PRPF6 CoA 259 (3) Q91YR7 218 (3)
NONO CoA/CoR 625/197 (1) Q99K48 472 (1)
PELP1 CoA 261 (5) Q9DBD5 504 (5)
SART3 CoR 286 (4) Q9JLI8 863 (4)
NCOR2 CoR 107 (7) Q9WU42 95 (7)
PSMC3 CoA 148 (1) A2AGN7 247 (1)
EHMT2 CoA 66 (5) A2CG76 282 (5)
KDM1A CoA 210 (4) A3KG93 100 (4)
ZFP318 CoR 35 (3) B0V2M3 30 (3)
EP300 CoA 31 (7) B2RWS6 107 (7)
FLNA CoA/CoR 6598/1307 (7) B7FAU9 6972 (7)
BRD8 CoA 62 (5) Q8R3B7 164 (5)
SUPERVILLIN CoA 53/44 (6) Q8K4L3 439 (6)
DDX17 — 584/336 (2) Q3U741 645 (2)
HDAC6 CoA 99 (4) Q3UG37 142 (4)
TRP53 CoA 1026/71 (1) Q80ZA1 1090 (1)
SRCAP CoA 57 (7) Q8BKT0 82 (7)
TRP53) involved. Another overrepresented pathway “chro-
matin remodeling by hSWI/SNF ATP-dependent com-
plexes” involves genes SMARCA4, ACTB, NR3C1, NF1,
ARID1A. A third overrepresented BIOCARTA pathway is
“control of gene expression by vitamin D receptor” with
EP300, SMARCA4, MED1, NCOA2, and ARID1A involved
(Table 3). All 3 pathways do not include the androgen
receptor.
33◦C. The Gene list of known AR-interacting proteins iden-
tified in the nuclear FLAG purifications of the 33◦C samples
(33 only + common, Table 1) was accepted as 56 DAVID
ID’s using DAVID bioinformatics resources [6, 7]. ARID1B
was not detected as DAVID ID and therefore not included
in the analysis. As with the samples from 37◦C,the gene
ontology tool “GOTERM BP FAT” gives the highest score to
the biological process (BP) “regulation of transcription” with
34 contributing genes (Table 2). Looking at overrepresented
pathways only 7 AR-interacting proteins are components
of the Kegg pathway “pathways in cancer”: EP300, AR,
CTNNB1, HSP90, STAT3, HDAC1, and TRP53. Proteins
RB1, DAPK3, and PIAS1 are not present in the 33◦C samples
(Table 3). Following on from that, only 5 of those genes have
been associated with prostate cancer (EP300, AR, CTNNB1,
HSP90, and TRP53) and the inhibitory function of RB1 is
missing (Table 3).
Again the BIOCARTA Chart brings up as overrepre-
sented pathways: “telomeres, telomerase, cellular aging, and
immortality”, but here with only 4 genes being involved
(XRCC5, XRCC6, HSP90, and TRP53) and RB1 missing.
“Chromatin remodeling by hSWI/SNF ATP-dependent com-
plexes” has NR3C1 and NF1 missing and gained 3 new
components with ARID1B, SMARCC1, and SMARCD1.
SMARCA4, ACTB, and ARID1A are present. The pathway
“control of gene expression by vitamin D receptor” has now
5 components present EP300, SMARCA4, but not MED1
and NCOA2 anymore. ARID1A is still present and the 2 new
components SMARCC1 and SMARCD1.
3.3. Analysis of Gene Lists with g : Profiler [8]. Identical gene
lists submitted to DAVID were also submitted to the
gene ontology online tool g : Profiler for functional char-
acterization. “Regulation of transcription” was not a high
scoring biological process” on this occasion, whereas “gene
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Table 2: Gene lists representing the biological processes (BP) “regulation of transcription” and “gene expression” identified by the
bioinformatics tools “DAVID” and “g-profiler” as being overrepresented among the known AR-interacting proteins of the N-TAP-mAR
purification. Listed are the interacting proteins, the AR is in bold face, that were unique for the proliferating cells (33), interacting proteins
that were unique for the nonproliferating cells (37), and interacting proteins common to both (common).
Regulation of transcription (BP) DAVID Gene expression (BP) g-profiler
33 Common 37 33 Common 37
KDM3A EP300 EP300
SMARCA4 SMARCA4
AR AR
WHSC1 MED1 WHSC1 MED1
CTNNB1 CTNNB1
MED17 NR3C1 MED17 NR3C1
PRPF6 PRPF6
KDM1A KDM1A
MED24 SP1 MED24 SP1
TRP53 TRP53
MYST2 MYST2
DDX5 SRC DDX5
DAXX DAXX
SMARCC1 GATA3 SMARCC1 GATA3
RBM14 SMARCD1 RBM14
BRD7 NPM1 BRD7
GTF2F1 CALCOCO1 GTF2F1 CALCOCO1
EHMT2 EHMT2
FLNA FLNA
KDM5B KDM5B
NONO NONO
NCOR2 NCOR2
NCOA2 NCOA2
PA2G4 PA2G4
RB1 RB1
STAT3 STAT3
HDAC1 HDAC1
SFPQ SFPQ
TRIM24 TRIM24
HDAC6 PRKDC
COBRA1 CALR
ATAD2 XRCC6
MCM3 SART3
BRD8
SMARCA2
KHDRBS1
ZFP318
TGFB1l
PSPC1
PIAS1
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Table 3: Top half: gene lists representing the BIOCARTA pathways “telomeres, telomerase, cellular aging, and immortality”, “chromatin
remodeling by hSWI/SNF ATP-dependent complexes” and “control of gene expression by vitamin D receptor” found to be overrepresented
among the known AR-interacting proteins identified in the N-TAP purifications by the bioinformatics tool DAVID. Bottom half: gene lists
representing the “Kegg pathway” “pathways in cancer”, and “prostate cancer” identified as being overrepresented among the known AR-
interacting proteins identified in the N-TAP purifications by the bioinformatics tool “DAVID” and “g-profiler”. Listed are the interacting
proteins that were unique for the proliferating cells (33), interacting proteins that were unique for the nonproliferating cells (37), and
interacting proteins common to both (common). The AR is bolded.
Cellular aging, telomeres, Chromatin remodelling by SWI/SNF Control of gene expression by
immortality (DAVID) ATP-dependent complexes (DAVID) vitamin D receptor (DAVID)
33 Common 37 33 Common 37 33 Common 37
EP300
NR3C1 MED1
ARID1A ARID1A
HSP90 ARID1B
SMARCD1 SMARCD1
RB1 SMARCC1 SMARCC1
XRCC5 SMARCA4 SMARCA4
XRCC6 ACTB NCOA2
TRP53 NF1
pathways in cancer pathways in cancer prostate cancer prostate cancer
DAVID (g-profiler) (DAVID) (g-profiler)
33 common 37 33 common 37 33 common 37 33 common 37
EP300 EP300 EP300
AR AR AR AR
CTNNB1 CTNNB1 CTNNB1 CTNNB1
DAPK3 DAPK3
HSP90 HSP90 HSP90 HSP90
PIAS1 PIAS1
RB1 RB1
STAT3 STAT3
HDAC1 HDAC1
TRP53 TRP53 TRP53 TRP53
expression” scored high at both temperatures, with many
genes overlapping in both categories (Table 2). Also here the
Kegg pathway components for prostate cancer are revealed
for both temperatures, but only 4 (HSP90, AR, CTNNB1,
and TRP53) as shown in Table 3.
37◦C. Kegg pathway: “pathways in cancer” is only detected
in the 37◦C samples, with 9 components represented (EP300,
STAT3, HDAC1, HSP90, AR, CTNNB1, TRP53, DAPK3,
and PIAS1). The gene ontology subgroups for “biological
processes” (BPs), “anatomical structure morphogenesis”,
and “embryo development” are overrepresented in the
37◦C samples and overlapping components are involved
(Table 4). “Embryo development” components are NCOR2,
AR, CTNNB1, KDM1A, PRKDC, SP1, MED1, SMARCA4,
HDAC1, TRP53, TGFB1l, PSMC3, and NF1. “Anatomical
structure morphogenesis” components are NCOR2, AR,
CTNNB1, ACTB, PRKDC, SP1, MED1, SMARCA4, HDAC1,
TRP53, TGFB1l, GSN, NF1, GATA3, STAT3, NR3C1, and
STAT3. Comparison of these 2 groups suggests a more spe-
cific function inmorphogenesis during embryo development
for NR3C1, GATA3, and STAT3 (strong evidence) GSN and
ACTB (weak evidence).
33◦C. Among cellular component profiling, the nBAF com-
plex is solely detected in the 33◦C samples with SMRCC1,
SMARCD1, SMRCA4, and ARID1A (not listed in tables).
These proteins are also components of the SWI/SNF chro-
matin remodelling complex.
3.4. Western Blot Analysis of Cofactors Identified Only in
Proliferating or Only in Nonproliferating PC1 Cells. The
observation that some AR-interacting proteins were only
detectable in proliferating cells and others only in nonpro-
liferating cells (Table 1) could simply mean that the quality
of the cell extracts varies and much less protein is present in
one of the extracts. Another reason might be that expression
levels of those proteins alter during cell proliferation, and
less or more protein is available for interaction with AR.
A third option is that the binding aﬃnity of AR to the
interacting proteins changes with the proliferation status of
the cells. To address these questions, we carried out Western
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Table 4: Gene lists for the biological processes (BP) “chordate embryonic development” and “embryo development” found to be
overrepresented among the known AR-interacting proteins identified in the N-TAP purifications from the 37◦C samples but not the 33◦C
samples by the bioinformatics tool “DAVID” and “g-profiler”. Listed are the interacting proteins that were unique for the nonproliferating
cells (37) and interacting proteins common to both (common). The AR is bolded. AR-interacting proteins identified only in the 33◦C samples
are not involved in biological processes addressed here. No counterpart for the biological process “anatomical structure morphogenesis”
could be identified by DAVID.
Chordate embryonic Embryo development (BP) Anatomical structure morphogenesis (BP)
Development (BP) DAVID g-profiler g-profiler
33 Common 37 33 Common 37 33 Common 37
NCOR2 NCOR2 NCOR2
SMARCA4 SMARCA4 SMARCA4
AR AR AR
MED1 MED1 MED1
NF1 NF1 NF1
SP1 SP1 SP1
PSMC3 PSMC3
PRKDC PRKDC PRKDC
KDM1A KDM1A
TRP53 TRP53 TRP53
CTNNB1 CTNNB1
TGFBI1 TGFBI1
NR3C1
HDAC1 HDAC1
GSN
GATA3
EP300 ACTB
STAT3
blots, probing those AR-interacting proteins which were
diﬀerentially expressed (Figure 4).
No major diﬀerences in expression were observed when
extracts were probed with AR-N20 and ACTB control
antibodies, but diﬀerences were found elsewhere. NR3C1 is
expressed at much higher levels in nonproliferating versus
proliferating P17 cells, and expression levels of SMARCC1
were slightly lower in nonproliferating (37◦C) PC1/P17 when
compared to proliferating cells (33◦C). The diﬀerence in the
amounts of AR copurified SMARCC1 in proliferating versus
nonproliferating is not as striking as it is for NR3C1, and the
amounts at “low expression” temperatures are probably too
small to be detected by mass spectroscopy. The proliferation
status of P17 cells seems to aﬀect SMARCC1 and NR3C1
expression levels per se as SMARCC1 expression is up and
NR3C1 expression is down in proliferating cells. However,
the loss of NR3C1 expression in proliferating cells is unlikely
to account for all the loss in AR binding observed here.
Similar loss of SMARCC1 expression in nonproliferating
cells does not account for all the loss in AR binding detected.
Therefore, expression levels of coregulators and binding
aﬃnity to AR may contribute to the diﬀerences observed
in the 33◦C and 37◦C coregulator profiles. The N-TAP-
mAR itself appears to increase GR expression levels by at
least 3 fold under nonproliferating conditions comparing GR
expression in PC1 and P17 input samples (Figure 4).
4. Discussion
We have developed the epithelial and mesenchymal mouse
cell lines P17 and M7 for copurification of AR-associated
protein complexes under native conditions. The two cell
lineages are derived from the proximal caput epididymus
(P17) and the mesenchyme of the fetal vas deferens (M7)
of the mouse. The decision to carry out preparative scale
N-TAP-mAR purification on PC1 cells rather than MFVD
cells was based on the observation that CTNNB1 and SRC-1
could not be copurified fromMFVD cells with our extraction
protocol, whereas in P17 copurifications both coactivators
were easily detected. Another advantage of choosing the PC1
cell line was the more abundant AR expression and the rapid
growth compared to the mesenchymal cells. One confluent
dish of PC1 gave about 5–10 times as much cell pellet than 1
confluent dish of MFVD.
To demonstrate proof of principle we used the newly
developed purification protocol to detect diﬀerences in AR
cofactor binding in cells grown under proliferating (33◦C)
and nonproliferating (37◦C) conditions. As expected, many
of the copurified proteins confirm the role of the AR
in chromatin remodelling machinery, transcriptional com-
plexes and associated with the cytoskeleton. The purification
protocol we use is relatively crude and results in enrichment
of 200–500 bp DNA fragments after a micrococcal nuclease
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Figure 4: AR interacting proteins SMARCC1 and NR3C1 are diﬀerentially expressed in proliferating versus nonproliferating P17 cells.
Western blot analysis of known AR coregulators identified by mass spectrometry only in AR FLAG copurifications from proliferating P17
cells (SMARCC1) and of a known coregulator identified by mass spectrometry only in AR FLAG copurifications from nonproliferating
P17 cells (NR3C1). SRC1 was not identified at all, neither in purifications from proliferating nor nonproliferating P17 cells. AR and ACTB
were identified in both FLAG copurifications from P17 cells by mass spectrometry. Compared to the other identified known AR interacting
proteins NR3C1, SMARCC1, and ACTB, a smaller portion of the total SRC1 present in the nuclear extract (P17 Input) interacts with AR
(P17 TEV). M is the size estimate by a prestained protein ladder in kilo Daltons (kDa).
digestion. The isolation protocol is nondenaturing and
keeps the chromatin fraction as intact as possible. No size
fractionation step is included, which could allow isolation
of larger chromatin fractions, especially heterochromatic
fractions which are not degraded by micrococcal nuclease.
This fraction could contribute to a background of unspecific
binding, which is diﬃcult to control for as this might not
occur in the PC1 control sample, where the “anchor” in
form of the N-TAP-mAR is missing. On the other hand,
the purification protocol is selecting for stable interactions,
because no cross-linking step is included in our purification
procedure.
We have not tested whether novel interacting proteins
identified with this approach are indeed associated with
AR or whether they are just contaminants. These potential
interacting proteins could be novel AR-interacting proteins,
but could also bind unspecific to the FLAG-M2-coupled
magnetic beads. Unspecific binding to the FLAG antibody-
coupled magnetic beads is estimated at 5% based on the
recovery of protein from the FLAG purification of the
PC1 control sample. This would mean that 1 out of 20
identified proteins is not part of the AR-associated complex.
Unfortunately we were not able to reduce this background
with an additional His purification step, because the FLAG
purified and protease (TEV) eluted fraction was not able to
specifically bind Nickel resin, probably caused by complex
components covering up the His tag. In this study we
concentrate only on a small proportion of all the potential
AR-binding partners identified, representing the already
known AR-interacting proteins. We show that our approach
has the potential to diﬀerentiate between proteins which
preferably form part of the AR complexes in proliferating
or nonproliferating conditions, and those proteins where
interaction is independent of the proliferation status of the
cells.
4.1. Functional Enrichments among the Known AR Cofac-
tors Identified with Two Diﬀerent Bioinformatics Resources.
Common pathways enriched for or overrepresented in
proliferating and nonproliferating AR FLAG purifications
were the biological processes “transcriptional regulation”
and “gene expression”. Considering that the androgen recep-
tor is classified as a transcription factor, high scores in
those categories are expected. Scoring surprisingly high
were BIOCARTA pathways not involving AR at all such
as “chromatin remodelling by hSWI/SNF ATP-dependent
complexes” and “control of gene expression by vita-
min D receptor (VDR)” (Figure 5), which involves the
WINAC chromatin-remodelling complex. Both WINAC
and SWI/SNF complexes have BAF components (Brg1-
associated factors). The requirement of the BAF complexes
has been shown in vitro for ligand-dependent transactiva-
tion by nuclear hormone receptors, such as vitamin D3
receptor, retinoid X receptor, and peroxisome proliferator-
activated receptor PPAR-γ [16]. It has also been shown in
vivo for reconstitution of glucocorticoid-receptor-(NR3C1-)
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Figure 5: AR-interacting proteins are WINAC complex components and transcriptional activators of VDR-mediated gene expression.
Presented is a simplified version of the BIOCARTA pathway “control of gene expression by Vitamin D receptor (VDR)” illustrating how
AR and VDR may compete for shared coregulators. (a) In AR copurifications from proliferating P17 cells (33◦C), the transcriptional
activators EP300, SRC1∗, and 5 proteins from the ATP, dependent chromatin remodelling complex WINAC: SMARCA4, ARID1A, ARID1B,
SMARCC1, and SMARCD1 were identified. Under proliferating conditions, AR would therefore compete with VDR for 5 WINAC
components and for 2 transcriptional activators. (b) In copurifications from nonproliferating P17 cells (37◦C) only 2 known AR-interacting
proteins identified were components from the WINAC complex: SMARCA4 and ARID1A. However, 4 proteins identified: EP300, NCOA2,
MED1, and SRC1∗ act as transcriptional activators in VDR, mediated gene expression. Under nonproliferating conditions, AR would
therefore compete with VDR for 2 WINAC components and 4 transcriptional activators. ∗SRC1 is a general transcription activator for
steroid receptors and also component of this pathway. SRC1 was not identified by mass spectrometry, but AR-associated in Western blots of
FLAG-purifications from nuclear extracts of proliferating and nonproliferating P17 cells (Figures 4 and 3(b)).
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dependent transcription [17], chromatin remodelling on
interferon and virus inducible genes [18] and in neural
development with a subunit switch in the npBAF (neu-
ral progenitors-specific) chromatin remodelling complex,
essential for the transition from neural stem/progenitors to
postmitotic neurons [19] but has never been associated with
AR. Also the Vitamin D3 receptor has not been identified as
AR-interacting protein neither in our purification (data not
shown) nor by others. It is however possible that AR transac-
tivation might be stimulated by components of the WINAC
complex. The VDR and the AR could therefore compete for
shared coregulators, which would explain the observation
that AR stimulation by androgens suppresses VDR [20,
21], while AR downregulation by siRNA stimulates VDR
levels in LnCAP cells [21]. WINAC complex components
might be potential coplayers in AR transactivation, which
could be tested with siRNA cotransfection experiments in
our cell line. G-profiler, which does not oﬀer a tool such
as the BIOCARTA, also identified BAF components as
being overrepresented. Another overrepresented pathway is
the prostate cancer pathway, which is picked up by both
bioinformatics tools. G-profiler does not identify EP300 as
a gene involved in prostate cancer as it is done by DAVID
(Table 3 bottom). Also the “Kegg cancer pathway” is picked
up by both bioinformatics tools: g-profiler identifies the
same list of genes among the known AR-interacting proteins
as “DAVID”, only that RB1 is not included in the g-profiler
gene list (Table 3 bottom).
For male genital development and PAIS relevant bio-
logical processes are “embryo development”, which is here
represented with 13 genes identified by g-profiler and 11
identified by DAVID. Of those 10 are overlapping (Table 4).
The embryonic genes identified by DAVID are restricted
to chordate development and do not include CTNNB1,
HDAC1 and TGFBI1, although CTNNB1 and HDAC1
“knock outs” in mouse have been shown to result in
developmental phenotypes [22, 23]. G-profiler did not pick
up EP300. A role of EP300 in patterning and development
was suggested by studies in mice in which EP300 expression
was disrupted [24]. Both bioinformatic tools David and g-
profiler complemented each other in this study in identi-
fying androgen receptor regulated pathways and biological
processes.
In future we aim to replace the endogenous AR with
N-TAP-mAR. We will hopefully be able to apply the FLAG
purification protocol tested in this study to identify diﬀer-
ences in the proteome caused by the respective AR mutation.
The protein purification approach taken here and shown to
identify diﬀerences in co-factor recruitment of AR under
proliferating and nonproliferating conditions is encouraging
to undertake further experiments aiming to identify specific
interaction protein profiles for AR mutants associated with
PAIS.
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